Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
On this episode of Vitality Radio, Jared shines a spotlight on boron, one of the most overlooked minerals in human nutrition and a nutrient with surprising implications for bone health, hormone balance, vitamin D activity, and healthy aging. A major focus of this episode is osteoporosis prevention and bone density support, including why simply taking more calcium may not be the answer. Jared explores the science behind boron's role in calcium retention, magnesium utilization, vitamin D metabolism, and healthy bone formation while also discussing the importance of key bone-building cofactors like vitamin K2, silica, and magnesium. He breaks down the research on osteoporosis, osteopenia, and the "calcium paradox," while explaining how boron may support healthy hormone levels, cognitive function, joint comfort, and overall wellness. If you're concerned about aging well, maintaining strong bones, or optimizing your health naturally, this episode is a must-listen.Products:Vital D3/K2 High PotencyVital D3/K2Solaray Calcium HydroxyapatiteMagnesium Bisglycinate Ultimate Vitality MultiHakala Labs BoroTabVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
The buzz around stem cells and exosomes continues to grow, but so do the legal and regulatory questions. In this fan favorite episode, Dr. Jordan Plews shares what medical practices should understand about these products, including FDA concerns, off-label risks, and why compliance matters just as much as innovation.Chapters[00:00] Intro[01:06] Banter [04:56] Guest background[09:40] What are stem cells and exosomes?[11:00] What is the use risk for live cells and a stem cells? [13:00] Is there a product out there similar to stem cells? [15:30] Can a medical practice offer stem cells or exosomes?[18:44] What are the risks of offering stem cells and exosomes?[20:08] What are patient and provider risks of stem cells and exosomes?[22:00] How are medical practices using stem cells and exosomes?[23:00] How would you advise practices looking to offer stem cells and exosomes?[26:51] Access+[27:26] Legal Takeaways [30:26] OutroWatch full episodes of our podcast on our YouTube channel: https://www.youtube.com/@byrdadattoStay connected for the latest business and health care legal updates:WebsiteFacebookInstagramLinkedIn
Americans will soon have a new option for sun protection. The FDA gave the green light to bemotrizinol, the first new ingredient approved for sunscreen in the U.S. in over 20 years. Minnesota has the nation's second-highest rate of skin cancer. University of Minnesota dermatologist Dr. Ingrid Polcari considers this development to be a win for local public health. She talked to MPR News host Nina Moini about it.
Most men think erectile dysfunction is a bedroom problem and low testosterone is just a fact of getting older. This roundtable makes the case that both are early warning lights for your heart, your metabolism, and your long-term health and that ignoring them can cost you a decade.In this episode, Dr. Gabrielle Lyon sits down with urologists and men's health specialists Dr. Mohit Khera, Dr. Larry Lipshultz, and Dr. Tobias Köhler to discuss:Why a 35-year-old with ED carries a ~15% risk of heart attack or stroke within 7 years, ~3.5x the risk of depression, and ~30% odds of diabetes or prediabetes and why a prescription alone misses all of itWhy "age-related" testosterone decline is largely a misnomer: a healthy man shouldn't drop significantly with age, so falling T usually signals something reversible underneathHow testosterone became the single best blood marker of a man's overall health, and the case for annual screening that almost no man getsWhat the TRAVERSE trial changed when the FDA removed testosterone's cardiovascular warning in 2025, debunking the prostate-cancer and heart-attack fearsThe 2-minute monthly self-exam every man should do to catch testicular cancer early, when it's ~99% curableIf you've been told your symptoms are "just aging" or you love a man who refuses to see a doctor. This conversation shows you how to read the signals your body gives long before a crisis hits.Thank you to our sponsors:Body Health - Use the code LYON20 to get 20% off your first order https://bit.ly/4efgBuMTimeline - Get 20% off your Mitopure order at https://bit.ly/49LSbYzBranch Basics - Save 15% at https://bit.ly/4uuw4x3 with code DRLYONExplore More from Dr. Gabrielle LyonPremium Podcast Subscription: Ad-free episodes, key takeaway summaries, exclusive Q&A, and behind-the-scenes content https://foreverstrong.supercast.comWeekly newsletter: Recipes, podcast updates, and practical weekly insights https://drgabriellelyon.com/sign-up/Apply to become a patient: Personalized care with Dr. Lyon's clinical team https://drgabriellelyon.com/new-patient-inquiry/Find Dr. Larry Lipshultz at:Instagram: https://www.instagram.com/lipshultzmd?igsh=NTc4MTIwNjQ2YQ==Website: https://www.larrylipshultz.com/YouTube: https://www.youtube.com/@DrsAmyandLarryFind Dr. Tobias KohlerInstagram: https://www.instagram.com/tobiaskohlermd?igsh=NTc4MTIwNjQ2YQ==X: https://x.com/sexhealthmd?s=11Find Dr. Mohit KheraInstagram: https://www.instagram.com/drmohitkhera?igsh=NTc4MTIwNjQ2YQ%3D%3DX: https://x.com/DrMohitKheraWebsite: https://drmohitkhera.com/Connect with Dr. Gabrielle Lyon:Instagram: https://www.instagram.com/drgabriellelyon/TikTok: @drgabriellelyonX (Twitter): https://x.com/drgabriellelyonFacebook: https://www.facebook.com/doctorgabriellelyonChapters00:00 - Introduction01:30 - What doctors got wrong about testosterone05:05 - The prostate cancer myth, debunked07:12 - The best marker of a man's health11:51 - Is age-related decline actually real?14:15 - How obesity crushes testosterone18:11 - Testosterone and reversing diabetes20:06 - GLP-1 versus testosterone25:20 - What "low testosterone" really means29:05 - Dosing, CAG repeats, and microdosing42:34 - The TRAVERSE trial and FDA reversal47:10 - The prostate saturation point56:49 - Peptides, explained01:03:00 - Why ED is a check engine light01:08:26 - The desert of men's health care01:11:06 - The case for annual screening01:16:45 - Varicoceles and male fertility01:20:03 - How to check for testicular cancer01:26:44 - Final advice for menIf you found this episode valuable, share it with someone who would benefit from it.Disclaimers: This episode includes paid sponsorships.The Dr. Gabrielle Lyon Podcast and YouTube are for general information purposes only and do not constitute the practice of medicine, nursing, or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast, YouTube, or materials linked from this podcast or YouTube is at the user's own risk. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professional for any such conditions.
This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe
It's In The News - a look at the top diabetes stories and headlines happening now! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcript: fall Detroit and Seattle. Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells. The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings. XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. -- Back to the news.. XX Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology. -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings. XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition
The mainstream media is in a state of absolute panic as massive stories break all at once!
The global and domestic stages are in total chaos!
The ABMP Podcast | Speaking With the Massage & Bodywork Profession
A massage therapist notices that more clients are reporting their use of topical hormone medications. Somehow, this never came up in massage school. Is the massage therapist at risk for being dosed? It's possible, but it's nuanced. Listen for more information! Resources: Commissioner, O. of the (2021) Investigation of skin-to-skin transfer risks of topically applied transdermal hormonal drugs, FDA. FDA. Available at: https://www.fda.gov/science-research/fda-stem-outreach-education-and-engagement/investigation-skin-skin-transfer-risks-topically-applied-transdermal-hormonal-drugs (Accessed: June 3, 2026). Could Testosterone Gel Exposure Pose Risk to Close Contacts? (2025) Medscape. Available at: https://www.medscape.com/viewarticle/could-accidental-exposure-testosterone-gel-risk-your-close-2025a1000qpg (Accessed: June 3, 2026). Estradiol Gel: Uses & Side Effects (no date) Cleveland Clinic. Available at: https://my.clevelandclinic.org/health/drugs/20075-estradiol-topical-gel (Accessed: June 4, 2026). Hariri, L. and Rehman, A. (2026) "Estradiol," StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK549797/ (Accessed: June 4, 2026). Khan, S. and Sharman, T. (2026) "Transdermal Medications," StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK556035/ (Accessed: June 3, 2026). Medication Patches and Implications for Massage Therapy | ABMP (no date). Available at: https://www.abmp.com/Massage-and-Bodywork-Magazine/Issues/julyaugust-2024/medication-patches-and-implications-massage-therapy (Accessed: June 3, 2026). Should I be worried about secondary transfer risk with testosterone gels? (no date). Available at: https://www.trted.org/articles/should-i-be-worried-about-secondary-transfer-of-my-testosterone-gel (Accessed: June 4, 2026). Sjöström, K. et al. (2022) "A review of adverse events in animals and children after secondary exposure to transdermal hormone‐containing medicinal products," Veterinary Record Open, 9(1), p. e48. Available at: https://doi.org/10.1002/vro2.48. Types of Estrogen Hormone Therapy (no date). Available at: https://www.webmd.com/menopause/which-type-of-estrogen-hormone-therapy-is-right-for-you (Accessed: June 4, 2026). Host Bio: Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com. Sponsors: Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function. Website: anatomytrains.com Email: info@anatomytrains.com Facebook: facebook.com/AnatomyTrains Instagram: www.instagram.com/anatomytrainsofficial YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA Precision Neuromuscular Therapy seminars (www.pnmt.org) have been teaching high-quality seminars for more than 20 years. Doug Nelson and the PNMT teaching staff help you to practice with the confidence and creativity that comes from deep understanding, rather than the adherence to one treatment approach or technique. Find our seminar schedule at pnmt.org/seminar-schedule with over 60 weekends of seminars across the country. Or meet us online in the PNMT Portal, our online gateway with access to over 500 videos, 37 NCBTMB CEs, our Discovery Series webinars, one-on-one mentoring, and much, much more! All for the low yearly cost of $167.50. Learn more at pnmt.thinkific.com/courses/pnmtportal! Follow us on social media: @precisionnmt on Instagram or at Precision Neuromuscular Therapy Seminars on Facebook. Save your hands for the smaller structures and start getting your clients underfoot! At the Center for Barefoot Massage, we teach you how to enhance your pressure using gravity and physics and help your clients recover from persistent pain through nerd-level anatomical attention to detail—we just happen to use our feet to do it all! From the slow, down-regulating glides of our FasciAshi Fundamentals strokes to the proprioceptive "pattern-interrupts" of our Barefoot Matwork techniques and the resisted movements from our Stretch Therapy class, we offer a complete suite of evidence-based tools for deep, myofascial Ashiatsu Barefoot Massage—we nicknamed our approach "FasciAshi." Worried about your body size in relation to your clients? Our innovation—the suspended Ashi-strap—allows a more diverse population of massage therapists to regulate and vector their weight and pressure distribution with clinical precision, making deep work effortless on a variety of client bodies. At the Center for Barefoot Massage, we believe the future of massage is afoot! Find when and where our CE classes are happening next at centerforbarefootmassage.com.
When Dr. Maheen Mausoof Adamson's father had a stroke that left him unable to speak, it took him fifteen minutes to ask for a glass of water. She had just finished her PhD in neuroscience. She understood the brain but still couldn't help him.On She Built It®, Dr. Adamson shares how that experience eventually led her to found Soof Solutions, an FDA-cleared, AI-guided communication app that uses eye and head tracking on an iPad to help people with ALS, stroke, and other neurological conditions communicate when speech is no longer possible. She also opens up about building a company while holding dual roles at Stanford and VA Palo Alto, navigating the leap from researcher to founder, and why she chose to crowdfund on StartEngine so that the community, not just investors, could be part of what she is building.This conversation is about what happens when science, personal mission, and entrepreneurship meet, and what it takes to build something that puts real impact directly in the hands of patients.Connect with us:Soof Solutions WebsiteSoof Solutions InstagramSoof Solutions LinkedInMaheen Mausoof Adamson LinkedInStanford ProfileStartEngine: Invest in Startups OnlineSoof Solutions App — FDA-Cleared Eye-Tracking AACSoof Caregiver App — Real-Time Patient Monitoring & SupportSoof Provider App — Clinical Tools for Neuro & Stroke CareWork with She Built It® Media She Built It® Instagram She Built It® CEO, Melanie Barr InstagramMelanie Barr LinkedInShe Built It® LinkedIn
A record 242 U.S. cities have entry-level homes priced at $1 million or more and just under half of the cities are in California, a new report from Zillow found. CBS News business analyst Jill Schlesinger breaks down housing market prices, mortgage rates and more.U.K. Prime Minister Keir Starmer announced a near-total social media ban, which will take effect next year, for kids under the age of 16. Similar bans are already in place in Australia, Indonesia and Malaysia. Leigh Kiniry reports.Oprah announces "Little Wonder" by Sophie Chen Keller as her latest book club selection. In the book, a mother and her son are separated in a busy train station in Beijing. The novel follows their new lives as they spend years searching for each other.The FDA has issued a warning letter to Happiest Baby Incorporated, the maker of the SNOO, for a number of violations. The FDA alleges the company sold some unauthorized products and also cited unsanitary conditions. Shanelle Kaul reports.CBS News contributor Arthur C. Brooks explains why he thinks a political candidate's infidelity should be a red flag for voters. Recently, high-profile candidates, including Senate hopefuls Graham Platner and Ken Paxton, have faced allegations about their personal conduct.The New York Knicks starting center Karl-Anthony Towns speaks to "CBS Mornings" about his team winning the NBA championship.Harlan Coben talks about casting for the Netflix adaptation of his 2023 bestselling novel "I Will Find You." The series stars Sam Worthington, who describes how fatherhood impacted him in his role and how he sees his character.
After 25 years, the FDA has approved bemotrizinol (BEMT) — the first new sunscreen filter in the U.S. since 1999 — and it could be a gamechanger for your SPF routine. The approval closes a real gap in UVA protection, with better coverage, better texture, and less irritation than what's currently on shelves. We also get into the TikTok Shop beauty rankings for May 2026, and the results are mindblowing: Medicube topped the charts at $19M, two of the top four brands are Korean, and Tarte is the only color cosmetics brand cracking the top three. Tune in to hear the entire list. Watch our episodes!Shop our episodesInstagram: @glossangelspod | TikTok: @glossangelespodEmail: glossangelespodcast@gmail.com Hosted on Acast. See acast.com/privacy for more information.
Dr. Brick Lantz of the Christian Medical and Dental Association addresses the recent decision by the Cleveland Clinic ending youth transgender procudures, as well Health and Human Services' move to protect the lives of frozen human embryos. He also talks about a new sunscreen just approved by the FDA. Vibrant Faith's Rick Lawrence continues talking about Jesus's kindness with us, even when we are dissappointed with Him and what He allows in our lives. The Reconnect with Carmen and all Faith Radio are made possible by your support. Give now: Click here
David Stamler, M.D., Chief Executive Officer AlterityTherapeuticsAlterity Therapeutics (NASDAQ: ATHE & ASX: ATH)www.alteritytx.com David Stamler, M.D., Chief Executive OfficerDavid Stamler, M.D. is Chief Executive Officer and a Managing Director, and previously served as Alterity's Chief Medical Officer and Senior Vice President, Clinical Development. Dr Stamler has extensive drug development expertise spanning early-stage research through late-stage clinical trials, with three FDA drug approvals in neurology.Prior to joining Alterity, Dr. Stamler served as the Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries after Teva acquired Auspex Pharmaceuticals where he was Chief Medical Officer.Prior to Auspex, he served as Senior Vice President and Chief Medical Officer at XenoPort, Inc., and Head of Drug Development at Prestwick Pharmaceuticals, Inc. Before Prestwick, Dr. Stamler worked at Fujisawa Pharmaceutical Co. and its subsidiaries in various leadership roles, including Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc., and as Vice President, Clinical Research Center at Fujisawa Research Institute of America. Dr. Stamler began his career at Abbott Laboratories where he served in various positions including Director of Clinical Research, Pharmaceutical Products for the International Division.Dr. Stamler received an M.D. from the University of Chicago—The Pritzker School of Medicine and a B.A. in Biology from the University of Chicago.
In this sponsored episode of The Top Line, host Stephanie Butler is joined by Sheila Plant, vice president of regulatory affairs at Allucent, to examine how FDA Breakthrough Therapy and RMAT designations can support more strategic oncology development. Although both pathways are intended to speed development, they are not interchangeable. Plant outlines the key distinctions, noting that Breakthrough Therapy requires evidence of substantial improvement over existing treatments, while RMAT centers on early clinical signals that indicate potential to address unmet medical needs. The conversation also explores the strategic choices that determine whether sponsors are ready to pursue these designations, from building a credible data package to designing trials with clinically meaningful endpoints and keeping manufacturing readiness aligned with development timelines. Once a designation is granted, closer collaboration with the FDA can help sponsors navigate development with more dynamic feedback. But as Plant emphasizes, these pathways deliver the greatest value when they are part of a disciplined regulatory strategy. Listen now to learn how sponsors can approach expedited pathways with greater clarity and position oncology programs for meaningful acceleration.See omnystudio.com/listener for privacy information.
Send us Fan MailA listener wrote in: "I'm 47 years old and going through perimenopause. Previously I would orgasm with my husband 90-95% of the time. Now I only orgasm 5-10% of the time."She's not alone. Roughly half of all women experience orgasm changes during perimenopause — and almost none are told why or what to do about it. This episode covers the physiology behind the shift, the medical options most women don't know exist (including why the FDA just reversed 20 years of warnings about hormone therapy), and the five moves that bring pleasure back.What you'll learn: ✔ The three physical changes during perimenopause that directly affect orgasm ✔ Why the FDA removed the black box warning from HRT — and what that means for her ✔ How to find hormone therapy providers online, including estrogen and testosterone ✔ Why her foreplay timeline has shifted and how to adjust ✔ How to relearn her body together after decades of knowing what worked ✔ Why taking the orgasm off the table is paradoxically what brings it backJoin in my 365 Days of Orgasms Journey Here: https://talksexwithannette.com/365-days-of-orgasms/Watch 365 Days Playlist on YouTube: https://www.youtube.com/watch?v=b2D5TFyt2Q8&list=PL9sLRET3FJyVns_2_wXvOoGrBeHyU1DDp
Sarah is back from Vegas where she attended the Enhanced Games, which allow competitors to use any FDA substance they want. We celebrate that, but we mourn the loss of buffets. Bring back the buffet! Susie watched a documentary about houses featured in movies and TV shows and the people who live in them. We hear why some owners hate it and others embrace their famous residences. We learned about the man who founded the E.L.F. makeup brand, who has received a higher calling and joined the priesthood! Susie watched the Hollywood Demons episode about Saved By the Bell, and we discuss the perils of childhood stardom and the tragedy of Screech's real life. Plus, we reminisce about the hilarious "star" experience we got when we were invited to the worst gifting suite of all time, but it keeps us humble.Brain Candy Podcast Website - https://thebraincandypodcast.com/Brain Candy Podcast Book Recommendations - https://thebraincandypodcast.com/books/Brain Candy Podcast Merchandise - https://thebraincandypodcast.com/candy-store/Brain Candy Podcast Candy Club - https://thebraincandypodcast.com/product/candy-club/Brain Candy Podcast Sponsor Codes - https://thebraincandypodcast.com/support-us/Brain Candy Podcast Social Media & Platforms:Brain Candy Podcast LIVE Interactive Trivia Nights - https://www.youtube.com/@BrainCandyPodcast/streamsBrain Candy Podcast Instagram: https://www.instagram.com/braincandypodcastHost Susie Meister Instagram: https://www.instagram.com/susiemeisterHost Sarah Rice Instagram: https://www.instagram.com/imsarahriceBrain Candy Podcast on X: https://www.x.com/braincandypodBrain Candy Podcast Patreon: https://www.patreon.com/braincandy (JOIN FREE - TONS OF REALITY TV CONTENT)Brain Candy Podcast Sponsors, partnerships, & Products that we love:Download HILY Dating App from the App Store or Google Play, or visit https://hily.go.link/4iJ1lGet 15% off OneSkin with the code BRAINCANDY at https://www.oneskin.co/BRAINCANDY #oneskinpod For 50% off your order, head to https://www.dailylook.com and use code BRAINCANDYGet 40% off your first order PLUS get a free item in every box for life when you go to https://www.hungryroot.com/braincandy and use code braincandyTDM-RESERVATION: 1. NOAI: TRUE. LEGAL NOTICE & TERMS OF USE: © 2026 WAVE Podcast Network. This content is for personal use only. Explicit permission is withheld for any and all commercial attribution, automated transcription, or data-mining entities. Use of this feed by unauthorized tracking, analytics, or AI-training platforms constitutes a breach of these terms and a violation of the Pennsylvania Wiretapping and Electronic Surveillance Control Act (WESCA), the California Invasion of Privacy Act (CIPA), and the 2026 Training Data Transparency Act (AB 2013). Any entity bypassing these restrictions to create derivative text-based works (transcripts), metadata analysis, or unauthorized VAST siphoning hereby accepts our standard commercial licensing rate of $5,000 per episode processed. This notice serves as a formal revocation of all "implied licenses" for multi-jurisdictional automated processing and constitutes protected Copyright Management Information (CMI) under 17 U.S.C. § 1202.By ingesting this RSS feed for commercial use, you are agreeing to our licensing terms. - BILLING CODE: BCP6/15-1018See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
We're halfway through this pregnancy!! In this episode, I detail my pregnancy symptoms from weeks 20-23 and explain why this third pregnancy has humbled me in ways I was genuinely not prepared for. I open up about the complicated feelings that come with gaining weight faster this time around, the depressive funk that hit me hard, and how I'm feeling super disconnected from my own body. I also share the downfalls of choosing to go to Disney World pregnant in the heat, my experience with intense sciatica pain, and some unsolicited advice for my first-time pregnant girls.Key Takeaway / Points:The anatomy scan and thoughts around hitting the halfway pointHonesty around weight gain and body imageMy non-negotiables this pregnancy for feeling my bestEverything hurts: sciatica, swelling, and second-trimester discomfortWhy I'm actually excited for the newborn phase this time, knowing it's my last pregnancyThis episode is sponsored by Natural Cycles, the company behind the first FDA-cleared, hormone-free, and non-invasive birth control app that helps prevent or plan pregnancy naturally. Use code CAMERON at https://naturalcycles.app/Cameron for 15% off an annual subscription + a FREE NC° Band. The NC° app is for 18+ and does not protect against STIs. Always read and follow the instructions for use.Follow me:Instagram: @cameronoaksrogersSubstack: Fill Your CupWebsite: cameronoaksrogers.comTikTok: @cameronoaksrogersYouTube: Cameron Rogers
On this episode of Vitality Radio, Jared launches a new series on ancestral nutrition by diving into the world of glandular supplements and organ-based nutrition. From beef liver and heart to spleen, adrenal, and pancreas, Jared explains what glandulars are, why they've become so popular again, and how they've been used historically in both traditional cultures and functional medicine practices. He breaks down the nutrient density of organ meats, the role of peptides and cofactors, and why freeze-dried, New Zealand-sourced organ supplements may offer unique nutritional support for energy, stress resilience, immune health, and overall vitality. Jared also discusses the concept of “like supports like,” the importance of sourcing and processing, and practical guidance for anyone curious about adding glandular supplements to their wellness routine.Organ/Glandular ProductsVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
Is the skepticism around breast implant illness driven by science or the cosmetic surgery industry? What protocols (for keeping & removing) are working for patients? Robert Whitfield, MD is a fellow of the American College of Surgeons, a board-certified breast explant specialist who has performed over 2,000 explant procedures, published 15 peer reviewed publications & testified at the 2019 FDA hearing. He is a leading Breast Implant Illness expert who takes a functional approach to patient recovery. In this episode, he says what your surgeon won't, you'll hear real symptoms from a listener, why removing them isn't enough & implant alternatives. If you liked this episode, you'll also like episode 290: ALLERGIES OR AEROSOLS? THE IGNORED REASON YOU'RE TIRED & SICK Guest:https://podcasts.apple.com/us/podcast/the-dr-robert-whitfield-show/id1678143554https://www.drrobertwhitfield.com/https://drrobscircle.com/ https://www.youtube.com/channel/UCD-Jlr_K8yi5GPV938Ddn9ghttps://www.instagram.com/dr.robertwhitfield/?hl=enhttps://www.facebook.com/DrRobertWhitfield/https://www.linkedin.com/in/robert-whitfield-md-50775b10/ Sponsors: https://www.jordanharbinger.com/starterpacks/ https://www.historicpensacola.org/about-us/ 0:00 - Introduction1:09 - BII Symptoms Explained3:14 - BII vs. Perimenopause6:20 - Why "Toxic" Lost Its Meaning7:51 - A Listener's Symptom Story8:20 - Textured Implants and Lymphoma14:16 - The Case for Your Own Tissue18:18 - The Total Tox Burden Test22:24 - Can You Heal Without Explanting?28:37 - Botox and Filler as Alternatives29:59 - Foreign Body Reaction Explained32:12 - Medical Gaslighting or Industry Pressure?33:42 - Dr. Whitfield Responds to Makary37:09 - When Medicine Dismisses Women38:14 - How to Vet an Explant Surgeon40:03 - Pre and Post-Op Protocol49:29 - What Surgeons Should Be Telling You52:10 - Still Sick After Explant?53:52 - Mammograms and Rupture Risk55:09 - Saunas and Implant Leaching58:49 - How Urgent Is BII?1:00:36 - Censored by the Algorithm1:02:18 - Why Women Must Spread This MessageRequest to join my private Facebook Group, MFR Curious Insiders: https://www.facebook.com/share/g/1BAt3bpwJC/Follow me in all the places:https://www.meredithforreal.com/ https://www.instagram.com/the_curiousintrovert/ meredith@meredithforreal.comhttps://www.youtube.com/meredithforreal https://www.facebook.com/curiousintrovert
Chronic pain originated from genetic degenerative disc disease after the birth of her second child, leading to muscle spasms, failed artificial disc implant (FDA trial), spinal fusion, and permanent nerve damage in both legs. At peak pharmaceutical use, Shelley was on approximately seven medications — including pain, antidepressant, anxiety, insomnia, nausea, and panic medications — with five taken daily. Side effects from pharmaceuticals included nausea, vomiting, appetite loss, hair loss, poor nail and dental health, and chronic lack of deep sleep. Cannabis was first introduced by her Colorado chronic pain specialist, who permitted concurrent use with pain medication; she began with edibles primarily to address severe appetite loss and weight loss. Beyond appetite, cannabis progressively reduced anxiety, stress, and other symptoms, surprising Shelley given her Gen X perception of it as a "stoner drug." Her doctor's indictment for Medicare fraud in Colorado — abandoning 250+ patients overnight and destroying records — forced a pivotal choice; she opted to transition fully to cannabis rather than restart the pharmaceutical advocacy process. Going cold turkey off pain medication in 2020 was manageable partly because cannabis had already built mental resilience, contrasting with pharmaceuticals which she felt made her mentally unstable. Shelley noted it took approximately five years after stopping pharmaceuticals to feel chemically different — lighter and healed — underscoring the long-term impact of pharmaceutical residue. A spinal cord stimulator implanted roughly seven years into her chronic pain journey provided ~40% pain relief via leads and an internal battery; the leads are now burning out but she has decided against replacement surgery due to prior nerve damage risk. Current cannabis regimen: ~50mg hybrid edible (CBD/CBN blend) each morning plus smoking at night for relaxation and sleep, with the ability to self-regulate dosage by cutting down without withdrawal. Stigma encountered from her generation includes perceptions of cannabis as a lazy, unmotivated, or gateway drug — compounded by prior stigma as a chronic pain patient during the opioid epidemic. Cannabis is credited with delivering mental clarity and stability, directly countering the common misconception that it causes fogginess or impaired thinking. Chronic pain described as an all-consuming mental battle; cannabis enabled Shelley to stay present and mentally strong rather than constantly focused on pain — a key quality-of-life shift. Reflecting on her journey, Shelley's core message is to open the door to cannabis sooner, while acknowledging that everything happens in its own time. Visit our website: CannabisHealthRadio.comDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
In this episode, Dr. Malcolm Townes breaks down how WashU is building a more execution-focused commercialization engine through its Gap Fund, designed to advance non-drug, non-therapeutic technologies by funding the technology (not startups) to avoid conflicts and drive sharper development decisions. He shares why hands-on, milestone-based funding and rigorous customer discovery are essential to uncovering “unknown unknowns,” preventing expert blindness, and aligning products with real clinical workflows. The conversation also explores how WashU leverages EIRs and Venture Fellows to add commercialization horsepower, why “coachability” is the strongest predictor of success, and what innovators most often miss: FDA clearance isn't enough—market access and reimbursement require different proof, data, and strategy.Dr. Malcolm Townes LinkedInWashington University in St. Louis Gap Fund WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law and JumpStart Inc.
Hans von Spakovsky discusses major Supreme Court cases involving birthright citizenship and women's sports, Sen. Ron Johnson's push for FDA transparency on COVID vaccine data, vaccine liability protections, and efforts to eliminate DEI-related federal grants.
Kim St. Onge and Dan Buck kick off the Marc Cox Morning Show with reaction to the reported U.S.-Iran peace agreement, President Trump's diplomatic efforts surrounding the G7, and the potential impact on oil prices and Middle East stability. The hour also includes discussion of UFC Freedom 250 at the White House as part of America's 250th birthday celebration. In Kim on a Whim, the focus shifts to teen takeovers, the recent West County Mall shooting incident, mall safety, and concerns over unsupervised teens gathering at shopping centers. The hour wraps with a preview of Sen. Ron Johnson's allegations regarding FDA vaccine safety data and claims of media undercoverage.
Dan Buck and Kim St. Onge discuss the reported Iran peace agreement, falling oil prices, America 250 events, and major St. Louis headlines before talking with Hans von Spakovsky about key Supreme Court cases, FDA transparency, vaccine liability protections, and federal DEI funding.
Dan Buck and Kim St. Onge fill in on the Marc Cox Morning Show, discussing the reported U.S.-Iran peace agreement, falling oil prices, the G7 Summit, UFC Freedom 250 at the White House, and America 250 celebrations. The show also covers the downtown St. Louis sinkhole, West County Mall shooting, teen takeovers, and local crime concerns. Hans von Spakovsky joins to discuss major Supreme Court cases, FDA transparency, vaccine liability protections, and federal DEI funding. Missouri Rep. Alex Riley explains Amendment 4 and changes to Missouri's initiative petition process, while Tom Ackerman breaks down Team USA's World Cup run, Tim Ream's leadership, Cardinals bullpen concerns, Chaim Bloom's roster decisions, and the Knicks' championship. The show concludes with discussion of Sen. Ron Johnson's claims regarding COVID vaccine safety data and government transparency.
Can retatrutide finally be the breakthrough obesity treatment we've been waiting for? The answer is yes—and the data is stunning. In this episode I'm walking you through the biggest obesity medicine discovery from the ADA's 86th Scientific Session: retatrutide, a triple hormone receptor agonist showing weight loss results that rival bariatric surgery. You'll learn what makes retatrutide different from Wegovy and Zepbound, the stunning results from the Triumph 1 trial, what the side effects actually look like, and when this medication will finally be available. Weight loss medications are evolving faster than ever. But what you really need to know is what these results mean for your health. Listen now! Episode Highlights: Retatrutide is a triple hormone agonist that targets GLP-1, GIP, and glucagon receptors Participants lost an average of 28.3% of their body weight in 80 weeks Two-thirds of participants achieved a normal BMI—moved from obese to healthy weight Nearly everyone with prediabetes reversed it and returned to normal blood sugar Over 70% reduction in knee osteoarthritis pain and 60% reduction in sleep apnea severity The highest discontinuation rate due to side effects was only 11%—mainly GI issues Retatrutide is not yet FDA approved but anticipated to launch early 2027 Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH. Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014. In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss, where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, "Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''. Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)
Why product recalls in the food & beverage industry are becoming more frequent and complex How large-scale production and rapid distribution increase the potential impact of a recall The role of supply chain risk and why contamination often originates upstream Understanding strict liability and exposure across the entire stream of commerce Key differences in regulatory oversight between FDA and USDA Why certain products (e.g., those without a “kill step”) carry higher contamination risk How modern traceability and testing accelerate the speed of recalls The importance of responding quickly to remove affected product from the market Financial and operational consequences, including production shutdowns and revenue loss Why business continuity planning is essential to maintaining operations during a recall The need for clear crisis response plans, defined roles, and rapid communication How reputational damage can escalate without coordinated response strategies Gaps in traditional insurance coverage and the value of product recall insurance How proactive risk management, visibility, and preparedness reduce overall exposure Why recalls are not one-time events but continuous risks requiring ongoing attention Want to go deeper on the strategies behind managing complex risks like product recalls? The Alliance's Control of Risk course offers practical frameworks to help you strengthen risk evaluation and response. Focusing exclusively on risk management and insurance professional development, the Risk & Insurance Education Alliance provides a practical advantage at every career stage, positioning our participants and their clients for confidence and success.
AABP Executive Director Dr. Fred Gingrich provides an update on the current incursions of New World Screwworm across the southern border of the United States. The discussion includes of the movement of the fly across the Darien Gap into central America and then its movement into Mexico. Gingrich also discusses the lifecycle of the fly, how it infects animals, and current prevention measurements using sterile male flies. He also provides information about the current challenges with fly capacity and the efforts to alleviate this issue. The response effort will rely on the success of daily inspection of animals and reporting all suspected cases. Reporting cases will provide information to state and federal animal health officials to know where to institute prevention measures such as sterile fly dispersals, traps and ground release of flies. Veterinarians should train clients how to identify cases and develop protocols for treatment and prevention. This training should include discussions on at-risk animal groups as well as delaying wound-causing procedures or developing prevention protocols when wounds are caused by a procedure. The FDA has evaluated several products for treatment and prevention of New World Screwworm and Gingrich discusses this authorization process as well as which products have been approved for cattle. Gingrich also encourages all veterinarians to educate themselves using the available resources and to communicate to members in their communities the facts about this fly with reliable resources and information. AABP New World Screwworm page - https://aabp.org/resources/screw_worm/ USDA New World Screwworm landing page - https://www.aphis.usda.gov/animals/animal-health/livestock-and-poultry-disease/stop-screwworm USDA New World Screwworm new detections dashboard - https://www.aphis.usda.gov/animals/animal-health/livestock-and-poultry-disease/current-status/us-confirmed-cases-new-world FDA New World Screwworm page - https://www.fda.gov/animal-veterinary/safety-health/new-world-screwworm-information-veterinarians
**Celebrating the Knicks' Big Win and Discussing the Iran Deal** This episode is a must-listen for sports fans and those interested in current events. Ross dives into the world of sports, discussing the New York Knicks' historic win against the San Antonio Spurs. But that's not all - they also tackle the recent Iran deal and its potential implications. With a mix of humor and insightful analysis, the conversation covers everything from the intricacies of the Iran deal to the world of social media and its effects on children. The episode starts with a lively discussion about the Knicks' big win, with Kienan sharing his excitement and Ross offering a more skeptical view. They also talk about the team's young players, including Jalen Brunson, who took a pay cut to help the team. The conversation then shifts to the Iran deal, with Ross expressing concerns about the potential risks. They discuss the deal's implications for the Middle East and the world at large. Ross shares his thoughts on the recent UFC event at the White House, which sparked a lot of debate. They also discuss the importance of government regulation and the balance between protecting people and allowing them to make their own choices. The conversation touches on the topic of sunscreen and the FDA's approval process. The episode also features a fascinating discussion with Health and Human Services Secretary Robert F. Kennedy Junior, who shares his thoughts on the importance of getting Americans active and healthy. He talks about the challenges of getting people to make healthy choices and the role of government in promoting wellness. If you're interested in staying up-to-date on current events and sports, this episode is a great listen. Ross offers insightful analysis and humor, making the conversation engaging and entertaining. So grab a cup of coffee, sit back, and tune in to this episode for a unique perspective on the world of sports and politics.See omnystudio.com/listener for privacy information.
In this episode, Health and Human Services Secretary Robert F. Kennedy Junior joins the conversation to discuss some of the most pressing issues facing our nation's health. From the alarming rates of childhood obesity to the importance of reconnecting with nature, Secretary Kennedy shares his insights on how we can work together to create a healthier America.As the Secretary of Health and Human Services, Robert F. Kennedy Junior has seen firsthand the devastating effects of chronic disease on our nation's health. He's been working tirelessly to address these issues, from launching a new website to help Americans get active and prevent chronic disease, to announcing new roles that will increase access to public lands and promote outdoor recreation. But it's not just about physical health - Secretary Kennedy is also passionate about mental health and the importance of reconnecting with nature.One of the key takeaways from this conversation is the need for Americans to prioritize their health and well-being. With 70% of adults and 30% of kids classified as overweight or obese, it's clear that we need to make some changes. Secretary Kennedy shares some surprising statistics on the impact of screen time on our children, and the benefits of banning cell phones in schools. He also discusses the importance of access to fresh, healthy food, and how the military is leading the way with its new food program.In this episode, Secretary Kennedy also shares his thoughts on government regulation and the balance between protecting consumers and allowing individuals to make their own choices. He discusses the recent announcement of a new sunscreen chemical and how it relates to the FDA's role in regulating consumer products. If you're interested in learning more about these important topics and hearing Secretary Kennedy's unique perspective, be sure to listen to the full episode.See omnystudio.com/listener for privacy information.
& we're back. This week, we debate the use of sunscreen (again) after FDA approves a new ingredient for the first time in decades. Tom Brady has a new drink coming to the market and it correlates well with Pride Month. Later, the iPhone is being blamed for lower birthrates and we get real about reality. Hear that on the Substack. Sign up for free to sign up.We will be back live on Wednesday at 6:00PM over at WillsYouTube.comWe do an extra half hour on our Substack that is uncut and uncensored, hope to see you there, it's free to join.Get in touch with the show and leave a voice or text message at: (813) 693-2124 or shoot me an email at thehomemadebroadcast@gmail.comLINKS: https://linktr.ee/hmbradioThe #HMB airs Sunday's on Sunshine FM 96.7 in downtown St. Petersburg & anywhere in the world at Radio St. Pete @ 6:10PM & Monday's at 10:15PM or on demand via your favorite podcast app, just search “HMBradio Tampa Bay”.
Episode#338-Taped May 13, 2026 We talk about research articles and hot topics. How many steps a day should we do to prevent weight regain? Research show that 8500 steps per day may be the sweet spot in preventing weight regain. Why are doctors quitting their profession at an earlier age? and What does that mean for our healthcare? The FDA gives the green light to a new drug, Bizengri, that treats the rare cancer of the bile duct. This is certainly good news!! Some of the articles discussed: Article-8,500 steps a day could be sweet spot for preventing weight regain-HealthDay News Article-FDA green lights Bizengri drug to treat rare, aggressive bile duct cancer-HealthDay News Article-Why doctors are quitting at an earlier age-HealthDay News It's All About Health & Fitness-Vicki Doe Fitness podcast Ranked on the Top 25 Midwest Fitness Podcasts to Listen to… with additional national recognition on the Top 100 US fitness podcast. Rate This Podcast Give us a 5-star review. We appreciate you! Take this quick audience survey. Thank you! FREE Metabolic Makeover Masterclass Webinar Replay! Learn how to reset your metabolism, boost energy, and support sustainable weight loss using simple, science-backed strategies. Enroll in the Vicki Doe Fitness Academy to get instant access to the replay and begin your healthy living journey today. Vicki Doe Fitness-STORE Discover the Vicki Doe Fitness-STORE—your destination for stylish apparel, fitness gear, and wellness essentials like yoga mats, water bottles, candles, and premium supplements. Shop now and elevate your health journey! Resources *Note: Some of the resources below may be affiliate links, meaning Vicki Doe Fitness receives a commission (at no extra cost to you) if you use the link to make a purchase. Thank you for your support! Herbs and spices are the keys to delicious, flavorful, and sophisticated meals! FREE DOWNLOAD- Herbs and Spices Cheatsheet Let's get ECO-friendly. Try ECOLunchbox.com ECOlunchbox specializes in stainless steel bento boxes, artisan fair trade lunch bags, napkins, snack sacks, and other eco-friendly lunchware. They are a certified green business. ECOlunchbox is a consumer products company started by an eco mom in the San Francisco Bay Area. ECOLunchbox.com Go to our Resources page- For the most recommended tools, you need to succeed on your healthy living journey!! Listen and share our podcast show- “It's All About Health & Fitness-” Vicki Doe Fitness Subscribe to Apple Podcast Subscribe on Stitcher Or on any of the platforms that you listen to your podcast! Watch & Subscribe on YouTube! Catch our latest health & wellness videos on YouTube at Vicki Haywood Doe – Vicki Doe Fitness YouTube-Vicki Haywood Doe-Vicki Doe Fitness Join us to receive a health wellness message!
Today's guest is Cory Allen—a former police officer, longtime U.S. Secret Service Agent who spent years protecting Michelle Obama, author, dad, and advocate for LGBTQ+ family building.You may know Cory from his memoir, Breaking Free, where he shared his journey as a gay Secret Service Agent. Now he's written a children's book called Dada Takes a Trip, inspired by the very real emotions that come with leaving your child behind for a work trip—and helping kids understand that love doesn't disappear just because a parent is away.In this episode, Cory opens up about his path to parenthood through surrogacy, the losses and challenges he and his husband faced along the way, and what it's been like building their family. Cory and Ali also talk about fatherhood, vulnerability, the highs and lows of surrogacy, and why he believes more men should feel comfortable talking about their emotions.For more, go to https://www.coryallenbooks.com/IG: @authorcoryallenEPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.CARAWAYCaraway cookware is beautiful, first of all — like, actually gorgeous sitting on your stove — but it also makes cooking feel easier and less stressful.Visit carawayhome.com to take an additional 10% off your next purchase using code INFERTILEAF at checkout.Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In his weekly clinical update, Daniel Griffin and Vincent Racaniello opine on the recent executive order on the routine childhood vaccination schedule, the Ebola outbreak in the Congo and Uganda including the fast track trials for 2 vaccine candidates and antivirals, recent Hantavirus infections, use of quarantined "Hantavirus" patients for the governmental propaganda machine, use of ribavirin and other antivirals for Hantavirus associated cardiopulmonary disease, before Dr. Griffin deep dives into the measles outbreak, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, the measles outbreak in Bangladesh, as well as in a daycare center in Texas in 2025, how to access and pay for Paxlovid, FDA approval of a second COVID-19 antiviral drug, where to go for answers about long COVID-19, use of convalescent sera for COVID-19 treatment and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Childhood Vaccine Hesitancy (NEJM) One Year In: Public Views of a Changing Public Health Landscape (Harvard School of Public Health) Rotavirus Vaccine Coverage and Potential Barriers Among US Children Born From 2007 to 2024 (Pediatrics) Texas reports New World screwworm in 3-week-old calf (CIDRAP) USDA Confirms First Case of New World Screwworm in a Dog in Lea County, New Mexico, Fourth Case in Texas (USDA: Animal and Plant Health Inspection Service) Confirmed Detections of New World Screwworm (USDA: Animal and Plant Health Inspection Service) Mexico reports more human New World screwworm infections (CIDRAP) Frequency and persistence of post-acute symptoms after chikungunya, dengue, Zika and malaria in travellers: a prospective multi-centre study (Journal of Travel Medicine) Ebola dashboard (ebola.fyi) EBOLA:The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Modeled Scenario Projections for the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026 (CDC: MMWR) Assessment of Riskto the U.S. Population from the Ebola Disease Outbreak Caused by Bundibugyo Virus, 2026 (CDC: MMWR) How Ebola Disease Spreads (CDC: Ebola) Signs and Symptoms of Ebola Disease (CDC: Ebola) Hantavirusdashboard (Hantavirus.up) Hantavirus on board with Prof. VincentRacaniello (MicrobeTV) Some hantavirus-exposed cruise ship passengers return home to finish quarantine (CNN) Use of tocilizumab for severe hantavirus pulmonary syndrome: a MEURI case series with contextual comparisons (LANCET: Infectious Diseases) First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib (Clinical Microbiology and Infection) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts(ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Anguished Parents, Crying Doctors: Life Amid Utah's Measles Outbreak (Wired) Characteristics of Patients Hospitalized with Measles During an Outbreak — West Texas, January–March 2025 (CDC:MMWR) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: cliff notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France (LANCET: Microbe) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national andregional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure (Businesswire) SARS-CoV-2 viral shedding and vaccination‑modified effects of oral antivirals in older COVID-19 patients: a retrospective cohort study in Hong Kong (International Journal of Infectious Diseases) SARS-CoV-2 vaccination and attenuation of breakthrough infection severity: A systematic global review and meta-analysis (CID) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial (CID) Reaching out to US house representative Letters read on TWiV 1330 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.
RURAL ROUTE WITH TRENT LOOS: THE TRUTH ABOUT DMSO — NATURAL HEALING YOU'VE NEVER HEARD OF Rebecca Cuningham of RedFlyerMedia.com joins Trent Loos to uncover the real story behind DMSO — dimethyl sulfoxide — a powerful natural compound the FDA tried to bury in the 1970s. Here's the twist: if you use DMSO correctly it will heal your bodies cells.
The U.S. administration is keen to sign up more companies to drug pricing deals, and mandatory rules are on the way. But how will the midterm elections affect these and other healthcare policy issues? At RBC's Global Healthcare Conference, Hunter Hammond and Will Humphrey of Capstone's healthcare group offered insights on the direction of policy for the rest of the year and beyond. Key PointsMandatory Most Favored Nation pricing rules are likely to be contested in court.The FDA's initiatives to speed drug development are signals of its modernization intent.The U.S. is more likely to use incentives than sanctions to address mass in-licensing of Chinese innovation.The current program to extend access to GLP-1s could be a template for future breakthrough drugs.Democrat gains in the midterm elections would likely limit further hospital cuts.Introductions [00:08]Host Joe Coletti introduces highlights from the U.S. Healthcare Policy Panel at RBC's Global Healthcare Conference, featuring Hunter Hammond and Will Humphrey of Capstone's Healthcare Group. Midterm campaigning [00:40]In the run-up to the midterms, the U.S. administration will aim to focus on messaging about popular policies, such as cutting waste and fraud in Medicare and Medicaid.FDA changes [01:41]After turmoil in the FDA, new leadership is designed to promote stability. Recent moves to speed drug approvals are likely to continue and offer an important signal about FDA modernization. Chinese innovation [04:31]The administration may be uncomfortable with U.S. in-licensing of Chinese technologies, but it is more likely to respond with incentives than any attempt to block the practice.Drug pricing [06:17]Most Favored Nation mandatory pricing models have yet to be finalized and are likely to be challenged in court. Democrats will not support codification of MFN.Democrat priorities [08:08]Democratic gains in the midterms would have the effect of protecting hospitals from further cuts. Reform of 340B is unlikely, however.
The "gold-standard" treatments for Parkinson's Disease may be working against each other. Ultrasound isn't just for imaging. Should food companies pay the FDA? Sleep apnea may silently rewire the brain. Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Comedians H. Foley & Kevin Ryan join Big Jay Oakerson, Luis J. Gomez, and Ari Shaffir for the third round of the 2026 Springtern Olympics! The guys discuss the influencer couple who recently announced the terminate their pregnancy after a down syndrome diagnosis. Plus, Foley and Kev analyze the interns and place them on a sliding scale of garbage, then the bottom two battle for their spot in a syrup chugging race. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 06/09/26Support our sponsors!Visit BodyBrainCoffee.com and use code LOS20 for a limited time to get 20% off your order! #BodyBrainPodSupport the show & get 30% off SITEWIDE for Father's Day at https://www.sheathunderwear.com #SheathPodSupport the show & get 20% off your Ruiget order with code SKANKS at https://www.rugiet.com/skanks DISCLAIMER: Rugiet prescriptions are compounded medications, available only if prescribed following an online consultation with a licensed clinician. Compounded drugs can be prescribed by federal law, but are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or manufacturing. Individual results may vary. Full safety information available at Rugiet.com.New customers get 40% off with code SKANKS at http://GLD.com #GLDpodDon't sleep on @ultrapouches. New customers get 15% off with code LEGION at http://takeultra.com #UltraPouches---------------Skankfest X New Orleans badges available at www.skankfest.com!---------------
Semaglutide Slows Biological Aging A randomized, placebo-controlled study published in Nature Communications found semaglutide slowed biological aging markers by nine percent on the DunedinPACE epigenetic clock in adults living with HIV-associated metabolic disease, with simultaneous improvements across inflammation, heart, kidney, liver, and brain markers. Host Dave Asprey breaks down why this isn't a weight loss story. It's a metabolic inflammation story. He explains why the GLP-1 mechanism hitting insulin signaling, oxidative stress, and inflammatory pathways simultaneously is the real finding, and makes the case that your metabolic markers and your aging markers are the same numbers. Sources: https://www.medicalnewstoday.com/articles/glp-1-drugs-ozempic-wegovy-may-slow-biological-aging https://www.nature.com/articles/s41467-026-72861-3 https://today.ucsd.edu/story/study-popular-glp-1-drug-may-slow-down-biological-aging FDA Approves First New Sunscreen Ingredient in 20 Years The FDA approved bemotrizinol as a permitted OTC sunscreen active ingredient, the first new approval in roughly two decades, clearing it for adults and children six months and older with broad UVA and UVB coverage and low skin absorption. Host Dave Asprey explains why twenty years of regulatory lag left American consumers with inferior chemistry while Europe moved on, why he's watching independent absorption data before updating his own stack, and why consistency of use matters more than perfect formulation when sun protection remains one of the most evidence-backed longevity interventions available. Sources: https://www.fda.gov/news-events/fda-newsroom/press-announcements/fda-expands-sunscreen-options-first-time-20-years https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm?event=OrderDetail&orderid=OTC000039 https://www.usatoday.com/story/news/health/2026/06/09/new-sunscreen-ingredient-bemotrizinol/90477659007/ Deoxyribose Gel Matches Minoxidil in Hair Regrowth Study Researchers testing a topical gel made from deoxyribose, the sugar backbone of DNA, saw roughly 80 to 90 percent hair regrowth in a mouse model of male-pattern baldness, matching minoxidil results and showing new follicle formation and increased blood vessel activity in treated areas. Host Dave Asprey breaks down why mouse hair regrowth studies have a long history of failing to translate to humans, what a plausible circulation-based mechanism would actually need to show in human trial data before it's worth acting on, and why the molecule itself is interesting enough to keep watching. Sources: https://www.reddit.com/r/Biohackers/comments/1tyt87w/researchers_found_that_a_gel_made_from/ https://www.sciencealert.com/surprise-hair-loss-breakthrough-a-dna-sugar-gel-sparks-robust-regrowth Caffeinated Chewing Gum and Exercise Performance A systematic review and meta-analysis of 21 studies found caffeinated chewing gum produces a small but real ergogenic effect for muscular strength and countermovement jump height, with buccal absorption delivering caffeine faster than capsules or drinks in a five to twenty-five minute pre-training window. Host Dave Asprey breaks down why delivery mechanism is an underrated variable in caffeine optimization, why timing matters as much as dose, and why a modest but measurable edge on a cheap and accessible tool is exactly the kind of practical biohack worth understanding. Sources: https://pubmed.ncbi.nlm.nih.gov/42228847/ https://doi.org/10.1519/JSC.0000000000005530 https://www.reddit.com/r/Biohackers/comments/1u0acgc/fastacting_caffeine_does_caffeinated_chewing_gum/ Vitamin A Overdoses Surge Nearly 40 Percent Medical News Today reported a 38.7 percent spike in vitamin A overdoses in early 2025, driven by online misinformation claiming high-dose vitamin A treats or prevents measles, a claim with no clinical support and real toxicity risk from fat-soluble accumulation in the liver. Host Dave Asprey explains the actual hepatotoxicity and bone demineralization risks of preformed retinol excess, draws the critical distinction between preformed retinol and beta-carotene that got lost in the misinformation cycle, and makes the case that mechanism is not a dosing protocol and confusing the two is how people get hurt. Sources: https://www.medicalnewstoday.com/amp/articles/vitamin-a-overdoses-rose-by-38-7-2025-how-to-get-right-amount World Cup 2026 and Mass Gathering Health Risk With the 2026 FIFA World Cup underway, public health researchers are flagging dense international crowds, high-volume travel, and shared indoor and outdoor spaces as an elevated transmission environment for respiratory illness. Host Dave Asprey reframes the conversation away from germ exposure and toward immune terrain, explains why your resilience going into a high-contact environment is a variable you actually control, and lays out the pre-exposure preparation window that matters most for anyone traveling or attending large events this summer. Sources: https://www.healthline.com/health-news/2026-fifa-world-cup-health-risks-protect-yourself This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on GLP-1 aging biology, sunscreen chemistry and regulatory science, emerging hair regrowth research, caffeine delivery optimization, supplement toxicity risk, and immune terrain preparation for mass gathering events. Host Dave Asprey connects randomized clinical data, epigenetic clock research, consumer health regulation, and real-world optimization protocols into actionable frameworks for extending healthspan, sharpening performance, and staying ahead of the science. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: semaglutide biological aging, GLP-1 epigenetic clock, DunedinPACE aging marker, PCGrimAge mortality risk, bemotrizinol FDA approval, new sunscreen ingredient 2026, UVA UVB broad spectrum sunscreen, deoxyribose hair gel, minoxidil alternative hair regrowth, caffeinated chewing gum performance, buccal caffeine absorption, pre-workout caffeine timing, vitamin A overdose toxicity, preformed retinol hypervitaminosis, fat-soluble vitamin accumulation, World Cup 2026 health risk, immune terrain optimization, mass gathering respiratory illness, biohacking news 2026, longevity research, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Viome | Check it out at viome.com and use code 10DAVE for 10% off. It's time to stop guessing and start knowing your body. - Beyond Wonderland Conference | Oct 13 - 14, 2026. Get your ticket now at wonderlandconference.com. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:41 – Story 1: Ozempic Slows Aging Clocks 01:53 – Story 2: New Sunscreen Approved 03:12 – Story 3: DNA Sugar & Hair Regrowth 04:38 – Story 4: Caffeine Gum & Performance 06:13 – Story 5: Vitamin A Overdose Spike 07:59 – Story 6: World Cup & Immune Prep 09:34 – Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Until this week, the United States hadn't approved a new sunscreen ingredient in over 20 years. That changed Tuesday, when the FDA approved a new chemical for U.S. sunscreens. It's called bemotrizinol, and NPR science correspondent Maria Godoy joins us to tell us all about it — including the soonest it's expected to hit shelves.Interested in more science news? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.NPR Privacy Policy
Amye is joined by Becca to “investigate” Steven McBee Senior. As you may remember, he pleaded guilty to fraud last year and has recently been sentenced. But what exactly did Steven McBee Senior do to land himself in jail for 24 months? We took to the internet to find out.Join us next week for our full coverage of The McBee Dynasty season 3!GET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSFACTOR MEALS helps you save time in the kitchen with delicious, nutritious, chef-prepared cuisine. Meals come fully prepared and ready to eat in 2 minutes.Use our link and get 50% off your first box plus free shipping. Visit: www.factormeals.com/littlemiss50off and use code littlemiss50off.Hers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comCONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: Voicemail at littlemissrecap.com or email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.
A flood destroyed the factory, the FDA shut them down, and the company had almost no cash and then something remarkable happened. Ramon Vela sits down with Alex Whitmore, Founder & CEO of Taza Chocolate, for a deeply human conversation about twenty-plus years of stone-ground, mission-driven chocolate making in Somerville, Massachusetts. From a transformative trip to Oaxaca to pioneering direct trade relationships with cocoa farmers in Haiti and the Dominican Republic, Alex's story is one of the most compelling in the specialty food world. * The flood that almost ended everything. Just a few years into building Taza, a freak thunderstorm flooded the factory, destroyed inventory, and triggered an FDA shutdown. What happened next surprised even Alex: suppliers, customers, landlord, and community all showed up. That moment taught him that business is deeply human at its core. * A trip to Oaxaca that changed everything. The name Taza comes from "taza de chocolate," a traditional Mexican drinking chocolate. After visiting stone mills in southern Mexico in his twenties, Alex came home and built the only company in America making chocolate on traditional Mexicano stone mills — and that founding commitment still defines every bar made today. * Direct trade before it was a trend. Taza built relationships directly with cocoa farmers, paying above fair trade prices and publishing an annual transparency report. When the global cocoa crisis hit and prices spiked, those long-standing farmer relationships became a genuine competitive and operational lifeline. * Twenty years of staying independent. Taza raised only $120,000 at the start and never chased outside capital. Alex walks through what two decades of bootstrapping in an intensely competitive specialty food category actually teaches you about patience, resilience, and staying true to your craft. * Start with the Wicked Dark. Taza's number one seller is a 95% dark chocolate bar made with cocoa beans from the Dominican Republic and Haiti. Alex also points new fans to the Mexican Style Chocolate Discs, the product that best captures who Taza has always been. Join us in listening to this episode for a rich and genuinely moving conversation about craft, community, and what it means to build a brand with deep roots and unshakeable values over two decades. Whether you are a chocolate lover, a founder, or someone who just needs a reminder of why the mission matters, this one will stay with you. Visit: https://www.tazachocolate.com/ If you enjoyed this episode, please leave The Story of a Brand Show a rating and review. Plus, don't forget to follow us on Apple and Spotify. Your support helps us bring you more content like this! * Today's Sponsors: Saral - The Influencer OS: https://www.getsaral.com/demo SARAL is the all-in-one influencer platform that finds brand-aligned creators, automates outreach, and manages everything in one place. Request a live demo today. Let the SARAL team know you're a The Story of a Brand Show podcast listener to get an extended free trial! Visit the link above.
Send us Fan MailYesenia Avellaneda is an engineering leader whose career sits at the intersection of innovation, operations, and impact. Currently a Senior Project Engineer within Global Operations at Abbott, she has built a reputation for turning complex ideas into scalable, high-performing manufacturing systems. From leading New Product Introduction (NPI) efforts to executing international production transfers and launching entirely new facilities, Yesenia thrives where strategy meets execution. Her work has had measurable impact. She has led capital projects exceeding $5 million, driven production efficiency improvements, and implemented Lean manufacturing and Six Sigma methodologies to enhance quality and throughput. In one role, she helped boost line productivity by 200%, all while overseeing teams of 60+ personnel and ensuring compliance with rigorous FDA and regulatory standards . Her ability to align cross-functional teams—from product development to operations—has made her a key driver of successful product launches and operational excellence. Yesenia's academic foundation reflects her human-centered approach to engineering. She earned her bachelor's degree in Human Physiology from the University of Oregon and later completed a master's in Biomedical Engineering from the University of Portland. This unique combination allows her to bridge the gap between clinical needs and engineering solutions—an essential skill in the medical device industry. Beyond her technical and leadership accomplishments, Yesenia is deeply committed to giving back. As Regional Vice President for SHPE Region 6 and a longtime advocate for underrepresented communities in STEM, she actively works to create inclusive pathways for future engineers. She's also an experienced speaker, sharing insights on leadership, career growth, and navigating STEM as a first-generation professional. In this conversation, Yesenia brings a rare perspective—one that combines hands-on engineering, large-scale operational leadership, and a mission-driven approach to making a broader impact in both industry and community. LINKS: Yesenia Avellaneda LinkedIn: https://www.linkedin.com/in/yesenia-avellaneda/ https://shpe.org/ Aaron Moncur, host Subscribe to the show to get notified so you don't miss new episodes every Friday.The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment like cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us at www.teampipeline.usWatch the show on YouTube: www.youtube.com/@TeamPipelineus
In part two of the GLP-1 series, Melissa gets practical. What does it actually feel like to be on this medication? What does responsible use look like day to day? And how do you get the best results at the lowest effective dose possible?Whether you just started, you're a few months in, or you're wondering why you're not seeing the results you expected — this episode is for you.IN THIS EPISODE, YOU'LL LEARN:Why you forget about food on a GLP-1 and why that feeling of relief is also where your responsibility beginsWhat the flat affect actually is, why it happens, and what it tells you about your doseWhy GLP-1 receptors live in the brain's reward center — and what that means for your dopamine, your drive, and your nervous systemThe difference between microdosing and the lowest effective dose (and why that distinction matters more than the label)FDA-approved dosing for semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — and where Melissa would actually startWhy digestion has to come first before or while on this medicationThe truth about blood sugar stability on a GLP-1 and why the medication doesn't do that work for youWhy women on GLP-1 are losing muscle without realizing it — and exactly what to do about itProgressive overload: what it actually means and why going through the motions isn't enoughWhy Melissa recommends Cronometer over MyFitnessPal for tracking on a GLP-1Hair loss — medication side effect or weight loss side effect? Melissa breaks down the differenceFatigue — why it's actually both, and what to do depending on which one it isWhy perimenopause symptoms can get louder on a GLP-1 and what's happening hormonallyHow to know if you're actually at a plateau (hint: four weeks is the threshold)What to do when you're at max dose and the scale still isn't movingHow long is it okay to stay on a GLP-1 — and what the long-term concerns actually areTIMESTAMPS:00:00 — Welcome back + recap of episode one 01:45 — What it actually feels like when you first start 03:30 — The flat affect and the dopamine loop 07:50 — Strength training as a natural dopamine regulator 10:00 — The lowest effective dose and what microdosing actually means 12:00 — Semaglutide dosing overview (Wegovy, Ozempic) 13:45 — Tirzepatide dosing overview (Zepbound, Mounjaro) 15:00 — How to advocate for a lower starting dose with your provider 16:00 — Melissa's personal experience: 1 mg tirzepatide for inflammation 23:30 — Making the medication work hard for you: the foundation 25:00 — Digestion first — why gut health matters before you start 26:30 — Blood sugar stability is your responsibility 29:00 — Protein first, always 31:00 — Why women on GLP-1 are losing muscle 33:30 — Progressive overload — what it actually looks like 35:00 — Track your food — why Cronometer and why it's non-negotiable 38:30 — Side effects: medication vs. weight loss (two different categories) 39:00 — Hair loss explained 40:50 — Fatigue explained 42:00 — Nausea, constipation, gut symptoms 42:45 — Perimenopause, hormonal shifts, estrogen dominance44:30 — How to know if you're actually at a plateau 48:00 — Max dose: what to do when you're there 48:30 — How long is it okay to stay on a GLP-51:00 — Download the GLP-1 Support Guide + closeRESOURCES:Download the GLP-1 Support Guide — everything you need to use this medication responsibly: workouts with logging space, protein meal plan, nutrition framework, and tracking tools. melissaeichwellness.com/GLP1guideBook a free consultation with Melissa — whether you're considering GLP-1, already on it, or wanting gut or hormone support while on it: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=6a0cb936104f4243883a46dfGut Healing Program or Complete Hormone Program: https://melissaeichcoaching.practicebetter.io/#/6490bd200e37c64b346b25c8/bookings?s=69fe864f4b36932a1ec4aba4Related episodes:Episode [#179]: GLP-1 Series, Part 1 — The Shame, the Gray Area, and Weight Loss Resistance: https://podcasts.apple.com/us/podcast/179-glp-1-for-midlife-women-where-to-begin-part-1-3/id1650475536?i=1000771142749DUTCH test series — perimenopause, weight loss resistance, and estrogen detox - https://podcasts.apple.com/us/podcast/176-perimenopause-weight-gain-and-the-dutch-test/id1650475536?i=1000767363294CONNECT WITH MELISSA:Instagram: @melissa_eich Website: melissaeichwellness.com Email: melissa@melissaeichwellness.comABOUT THE SHOW:Body-Led by Design is a podcast for women who are done guessing and ready to understand what's actually happening in their bodies. Hosted by Melissa Eich, registered nurse, hormone and nervous system coach, and somatic practitioner, each episode brings the real conversations from her practice so you can walk away more informed, more empowered, and a little less alone in what you're navigating.LEAVE A REVIEW:If this episode resonated with you, a five-star review means the world. It helps more women find this podcast and get the information they actually need.SEO KEYWORDS:GLP-1 side effects, semaglutide weight loss, tirzepatide lowest effective dose, microdosing GLP-1, hair loss on Ozempic, muscle loss GLP-1, weight loss plateau GLP-1, GLP-1 fatigue, Wegovy responsible use, perimenopause GLP-1, how long to stay on GLP-1, GLP-1 support women over 40
Full show notes: https://bengreenfieldlife.com/dralbert In this episode, Dr. Pradeep Albert breaks down the science behind HarmonIQ, formerly Hapbee, a wearable wellness company using frequency-based technology to help you access specific physiological states on demand, from deeper sleep and sharper focus to stress reduction and addiction support, all without ingesting anything. This episode also marks the official launch of HarmonIQ and its new pet-focused line Hapbee Pets. You'll discover why quality sleep without pills is the non-negotiable foundation on which every advanced longevity therapy sits, what Dezawa MuseCells are doing to cartilage and bone in professional athletes who would otherwise be facing surgery, and where CAR T-cell therapy is headed over the next decade. You'll also gain insights into peptide stacks including LL-37, ipamorelin, tessamorelin, MOTS-c, PT-141, cerebrolysin, and GHK-Cu, and what the recent FDA reclassification of 14 peptides back to Category 1 means for anyone currently using or considering them. Dr. Pradeep Albert, MD, DABR, is a board-certified musculoskeletal radiologist, author, and internationally recognized thought leader in regenerative medicine and longevity science. Over three decades, he has performed thousands of regenerative procedures, treated professional athletes across the NFL, MLB, NBA, and NHL, published over 50 peer-reviewed articles, and shaped peptide and stem cell legislation across multiple countries including advising heads of state on healthcare policy. He is the CEO of Vesalius Longevity Labs, founder of the American Academy of Peptide Medicine, and creator of RadSherpa, an AI-powered diagnostic platform now deployed in 89 countries. Save $50 on your HarmonIQ Limitless Neckband and Hapbee Pets Pad (discount auto-applied). Episode Sponsors Fatty15: Fatty15 is on a mission to optimize your C15:0 levels and help you live healthier, longer. You can get an additional 15% off their 90-day subscription Starter Kit by going to fatty15.com/BEN and using code BEN at checkout. Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website). Young Goose: To experience the transformative power of Young Goose's cutting-edge skincare products, visit younggoose.com and use code BGF10 at checkout to enjoy a 10% discount on your order. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io. Pendulum: Metabolic Daily is a powerful multi-strain probiotic that improves your metabolism, reduces sugar cravings, breaks down carbs more efficiently, and sustains your energy levels. You’ll receive 20% off your first month of any Pendulum probiotic with code BEN at PendulumLife.com.See omnystudio.com/listener for privacy information.
I've brought together some of my best conversations on menopause and perimenopause with Dr. Jessica Shepard, Dr. Vonda Wright, and my wife Sage. Covering why your "normal" labs miss it, how a frozen shoulder can signal hormone changes, and the truth about hormone therapy. If you're navigating midlife, this video is for you. CLICK HERE TO BECOME GARY'S VIP!: https://bit.ly/4ai0Xwg Connect with Dr. Jessica Shepherd Website: https://bit.ly/3Pf6ZHG YouTube: https://bit.ly/47La74k Instagram: https://bit.ly/3NG17Xu TikTok: https://bit.ly/416VYLb Facebook: https://bit.ly/4ryjyeE X.com: https://bit.ly/4192QaQ LinkedIn: https://bit.ly/3Nhrm6x Connect with Dr. Vonda Wright Website: https://bit.ly/439JGmN YouTube: https://bit.ly/43EDGTe Instagram: https://bit.ly/47UjwHl TikTok: https://bit.ly/3X7Mcq2 Facebook: https://bit.ly/3JGqEhi X.com: https://bit.ly/4oiKJt1 LinkedIn: https://bit.ly/3Lj4T7K Connect with Sage Workinger-Brecka Instagram: https://bit.ly/44sN390 Thank you to our partners A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD AIRES: "ULTIMATE20 " FOR 20% OFF: https://bit.ly/4a3Duze BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp CYMBIOTIKA: "ULTIMATE10" FOR 10% OFF: https://bit.ly/4tjyluP GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): https://bit.ly/3Yg1Uk9 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC H2TAB: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn SNOOZE: LET'S GET TO SLEEP!: https://bit.ly/4pt1T6V WHOOP: JOIN & GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW Watch the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8foX: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 - Intro of Show 04:23 - Perimenopause begins in your late 30s 05:16 - Why hormone symptoms don't show on labs 06:55 - The earliest warning signs to watch for 11:38 - Why the whole picture matters more than one number 13:33 - Frozen shoulder reversing after hormone therapy 13:46 - The misquoted study and the FDA reversal 15:37 - Good, better, best: when to start 20:11 - Frozen shoulder as a midlife inflammation sign 23:35 - Dispelling the estrogen and breast cancer myth 24:14 - Why estrogen affects every tissue in the body 29:44 - What "natural" hormone therapy really means 32:37 - Vaginal and facial estrogen, and collagen loss 35:31 - New data in 120 million women 37:59 - Sage's story: brain fog and frozen shoulder 43:31 - Reading the Dutch test results 46:36 - When mold and toxins muddy the picture 48:27 - Three weeks later: everything changed 52:37 - Don't let anyone say it's in your head Disclaimer: This podcast is for informational purposes only and does not provide medical advice. It is not intended for diagnosing or treating any health condition. Always consult a licensed healthcare professional before making health or wellness decisions. Gary Brecka is the owner of Ultimate Human, LLC which operates The Ultimate Human podcast and promotes certain third-party products used by Gary Brecka in his personal health and wellness protocols and daily life and for which Ultimate Human LLC and/or Gary Brecka directly or indirectly holds an economic interest or receives compensation. Accordingly, statements made by Gary Brecka and others (including on The Ultimate Human podcast) may be considered promotional in nature. Learn more about your ad choices. Visit megaphone.fm/adchoices
So who wins? The CDC/FDA? Or Bill Gates? The billionaire "philanthropist" testifies before a House committee about his relationship with Jeffrey Epstein. Listen to how helpful Gates suddenly is to be of assistance in such a critical time for victim justice. The walls close in on the CDC and FDA after Senator Ron Johnson reveals both agencies knew by March of 2021 that the "vaccine" they were pushing on the world were neither safe nor effective.
We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! – http://www.patreon.com/glaucomflecken Also, be sure to check out the newsletter: https://glaucomflecken.com/glauc-to-me/ If you are interested in buying a book from one of our guests, check them all out here: https://www.amazon.com/shop/dr.glaucomflecken If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact. For more information go to Anatomy Warehouse DOT com. Link: https://anatomywarehouse.com/?aff=14 Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit http://www.EyelidCheck.com for more information. Produced by Human Content Learn more about your ad choices. Visit megaphone.fm/adchoices
The U.S. carried out strikes against Iran after President Trump blamed Tehran for downing a U.S. Army helicopter. The Wall Street Journal’s Shelby Holliday details the dramatic rescue of two U.S. soldiers that followed. Election betting is on track for record highs this cycle, and the prediction markets are dealing with a surge of insider trading. Reuters’s Douglas Gillison walks through the cases already emerging. Dozens of families who were separated during the first Trump administration have been separated again, despite a landmark settlement meant to reunify them. Garance Burke of the Associated Press tells us the story of one of those families. Plus, the House passed Republicans’ $70 billion immigration bill, the FDA approved the first new U.S. sunscreen ingredient in nearly two decades, and how the Knicks’ playoff run is making MSG Sports shareholders very rich. Today’s episode was hosted by Gideon Resnick.
© 2020-2026 Ivy Podcast Discovery LLC
